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INTRODUCTION
The treatment for children and adolescents with acute
lymphoblastic leukemia (ALL) can lead to multiple adverse
effects, including a poor physical capacity. Accordingly,
several studies have reported that survivors of ALL may
experience muscle weakness, even years following their
remission.1,2 However, it has not yet been determined
whether patients who are currently receiving treatment for
ALL present with impaired strength.
To date, only a single pilot study compared muscle
strength in ALL with healthy controls.3 Using an isometric
strength assessment, the authors found that the ALL patients
were weaker than their healthy peers. Importantly, the
children with ALL demonstrated a progressive weakening
from the initiation of delayed intensification phase through
the next 28 days, suggesting that muscle strength may
fluctuate during ALL treatment. Understanding the time
course of treatment-induced muscle strength impairments
can help to determine the timing of exercise training
intervention,3 which is known to benefit ALL patients.4-6
The present case-control study aimed to characterize
muscle strength in children who were receiving mainte-
nance therapy for ALL and to compare this strength to that
of age-, gender-, and BMI-matched healthy controls.
METHODS
Subjects
Ten patients with ALL (ALL group) were recruited from
the Children’s Institute of the School of Medicine,
University of Sa˜o Paulo (Sa˜o Paulo, Brazil). The inclusion
criteria were the following: 1) children and adolescents (12-
16 years of age) who were receiving maintenance therapy
for high-risk ALL; 2) patients who had undergone more
than six months of treatment; 3) patients with a preserved
cardiac structure and function as assessed by an echocar-
diogram; and 4) patients with an absence of musculoskeletal
disturbances that may preclude their participation in the
strength assessment. The patients’ characteristics are shown
in Table 1. A group of ten age-, gender-, and BMI-matched
healthy children were recruited using an advertisement and
served as the control group (CTRL group). None of the
patients were involved in a structured physical activity
program for at least six months prior to testing, whereas the
healthy children were only engaged in regular physical
education classes (twice a week, 50 min per class). None of
the participants had previous experience with the isokinetic
strength test. The present study was approved by the
institution’s Ethics and Committee Review Board. The
subjects’ parents provided written informed consent after
receiving a complete verbal and written explanation of the
study’s objectives and the associated risks and benefits.
One, one and eight of the patients in the ALL group were
entered into the GBTLI–99, GBTLI–2009 and PROP-II-97
protocols, respectively. The GBTLI-99 protocol (Brazilian
Group of Childhood Leukemia Treatment) included the
administration of mercaptopurine (50 mg/m2/day-1) and
methotrexate (25 mg/m2/week-1). The patients also received
vincristine (1.5 mg/m2) and dexamethasone (4 mg/m2) for
seven days. The GBTLI–2009 protocol included the adminis-
tration of methotrexate (200 mg/m2) every 21 days, leucov-
orin plus mercaptopurine pulses (100 mg/m2/day-1) for ten
days, vincristine (1.5 mg/m2) and predinisone (40 mg/m2/
day-1) every four weeks for seven days. GBTLI–99 and
GBTLI–2009 also included intrathecal chemotherapy with
methotrexate, citarabine and dexamethasone every eight
weeks until the 106th week. The PROP-II-97 protocol (Insti-
tutional Protocol of the University of Sa˜o Paulo) included the
administration of the following medications for 80 weeks:
methotrexate (2 g/m2/week-1) plus mercaptopurine (75 mg/
m2/day-1) for three weeks; cyclophosphamide (250 mg/m2/
day-1) for four consecutive days followed by etoposide
(250 mg/m2/day-1) for three consecutive days; teniposide
and citarabine (300 mg/m2/week-1 and 250 mg/m2/dose/
week-1, respectively) for three weeks; citarabine (15 g/m2/
day-1) for two consecutive days and methotrexate (40 mg/
m2/week-1) with mercaptopurine for six weeks. After the 80th
week, the patients were given methotrexate (40 mg/m2/
week-1) with continuous daily mercaptopurine and vincris-
tine (1.5 mg/m2) pulses every six weeks and dexamethasone
(3 mg/m2/day-1) for seven days until the 120th week.
Isokinetic strength assessment
To assess the lower- and upper-limb isokinetic strengths,
we measured the concentric knee and elbow flexion and the
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extension strength using a calibrated isokinetic dynam-
ometer (Biodex System 3, Biodex Medical Systems, NY,
USA). Before testing, the patients were familiarized with the
procedures. The testing sessions were comprised of a
standardized procedure that included a 2-min warm-up
period on a cycle ergometer at moderate intensity. The
patients were seated in the dynamometer’s chair with 90˚ of
hip flexion. The knee of the dominant leg was positioned
near the apparatus’ lever arm, and the anatomical axis of
rotation of this joint was aligned with the dynamometer’s
rotation axis. The contact pad was placed approximately
3 cm superior to the medial malleolus with the foot in a
plantigrade position. The range of motion was set from 90˚
of knee flexion to 10˚ of knee extension. For the elbow
flexion/extension assessments, the dynamometer’s power
head was rotated to 30 .˚ The limb rest-device was used to
support the patient’s arm with the elbow slightly beyond
the end of the pad to allow for full extension. The elbow’s
axis of rotation was aligned to that of the dynamometer. The
subject then gripped the handle bar in a neutral forearm
position. The length of the attachment shaft was adjusted
while moving through the range of motion so that the wrist
was neither compressed nor stretched when gripped firmly
to the handle bar. The range of motion for the elbow test
was set at 100˚ from the fully extended position (with full
extension = 0 )˚.
During both of the tests (i.e., concentric knee and elbow
flexion/extension), the patients were asked to perform five
maximal repetitions to determine the peak torque (PT),
normalized peak torque (PT/BW), total work (TW) and
maximum work performed in a single repetition (Wmax).
These values were recorded at 30 and 60 /˚sec for the
elbow and knee, respectively. During the tests, the verbal
encouragement was consistent and standardized.
The dynamometer was calibrated according to the
manufacturer’s calibration procedure. At the start of each
test, a passive determination of the effects of gravity on the
limb and lever arm was performed. Additionally, straps
were used to minimize unwanted body movements. When
lower-limb was tested, patients were instructed to keep
their arms crossed at their chest.
Statistical analysis
Between-group comparisons of all of the strength para-
meters were performed using an unpaired Student’s t-test.
The data are expressed as mean ¡ standard deviation.
Differences with p#0.05 were considered to be statistically
significant.
RESULTS
The children in the ALL group exhibited a decreased knee
extension peak torque (PT) for the right (29.8%; p = 0.05) and
left limbs (30.8%; p = 0.02), and a lower normalized peak
torque (i.e., peak torque to body weight, PT/BW) than the
CTRL group for the right (24.3%; p = 0.05) and left limbs
(21.1%; p = 0.06) (Figure 1A and B). Additionally, the ALL
group exhibited a higher degree of unbalance between the
flexors and extensors than the CTRL group (for the right
limb: p = 0.05; Figure 1A). The children in the ALL group
also expended less total work during knee extension than
their healthy peers (right limb: 25.1%, p = 0.03; left limb:
23.9%, p = 0.02). Additionally, the maximum amount of
work that was performed during a single knee extension
repetition was lower for the ALL group when compared to
the CTRL group for the right (22.6%, p = 0.04) and left limbs
(22.3%, p = 0.008) (Figure 1C and D). Moreover, the time-to-
peak torque during the concentric knee flexion was
significantly greater for the ALL group when compared to
the CTRL group in the right (868¡299 vs. 594¡234 ms,
respectively; p = 0.03) and left limbs (696¡256 vs.
542¡203 ms, respectively; p = 0.05). No differences were
observed with regard to the time-to-peak torque during the
concentric knee extension.
Our evaluation of the upper limbs revealed that the
children in the ALL group exhibited a greater disparity in
their left limb balance between the flexors and extensors
when compared to the CTRL group (left limb: p = 0.002
Figure 2B). The total work expended by the elbow extensor
was also less for the ALL group when compared to the CTRL
group for the right (9.5%, p = 0.04, Figure 2C) and left limbs
(9.4%, p = 0.002, Figure 2D). The time-to-peak torque during
the concentric elbow flexion was significantly greater for the
ALL group when compared to the CTRL group for the right
(1627¡670 vs. 1164¡543 ms, respectively; p = 0.02) and left
limbs (1723¡453 vs. 1157¡563 ms, respectively; p = 0.02). No
differences were observed with regard to the concentric
elbow extension values.
DISCUSSION
The aim of the present study was to characterize the
muscle strength in children who were receiving maintenance
Table 1 - Physical characteristics and treatment protocols for the patients in the ALL group.
Patient Gender Age (years)
Weeks elapsed since
start of treatment Risk factor Treatment Protocol BMI (kg/m2)
1 F 12 116 High PROP-II-97 19.5
2 F 12 115 High PROP-II-97 18
3 F 13 30 High GBTLI-2009 19.5
4 F 13 117 High PROP-II-97 22.9
5 F 13 30 High GBTLI-99 21.1
6 F 14 98 High PROP-II-97 21.8
7 M 15 70 High PROP-II-97 20.7
8 F 15 70 High PROP-II-97 22.5
9 F 16 30 High PROP-II-97 24.8
10 F 16 112 High PROP-II-97 26.9
Mean 13.9 78.8 - - 21.7
SD 1.5 37.8 - - 2.65
All patients were at high risk.
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treatment for high-risk ALL. We observed that these patients
generally presented with decreased muscle strength relative
to their healthy control peers.
Although several studies have reported muscle weakness
in long-term survivors of ALL,1,2 there is a paucity of data
regarding the time course of the strength impairment in this
disease. Marchese et al3 reported a decreased isometric
strength and function in children with ALL early in their
course of treatment, with the weakest muscle strength
occurring on the 28th day of the delayed intensification
phase. Our present data are consistent with the idea that
muscle weakness is a relevant clinical manifestation in
patients with ALL and further extend this notion to patients
who are in the maintenance phase of ALL therapy.
It has been suggested that muscle weakness in patients
with ALL is the result of several combined factors, such as
impaired neuropsychological functioning, gross and fine
motor disturbances, alterations in growth, cardiac and
endocrine function, vincristine- and corticosteroid-induced
muscle wasting, and hypoactivity, with the latter-most factor
playing a key role in the decline in strength.7 Accordingly, it
seems reasonable to speculate that any reduction in daily-
living activities would compromise the muscles of the lower
limb, a notion that is supported by our observation of an
impaired peak torque (both absolute and normalized) in the
muscles of the lower but not upper limbs. In practical terms,
it seems reasonable to recommend that lower-limb strength-
ening exercises must be incorporated in a training program
for patients with ALL during the maintenance phase of their
treatment.
Another noteworthy finding is the reduced time-to-
peak torque that we observed in the upper and lower
limb flexors. The ability to produce torque rapidly has
been positively associated with balance and functionality
in the elderly.8 In children, there is evidence suggesting
that knee-flexor peak torque is an important contributor
to retaining balance following an induced forward sway,
thereby reducing the time needed to stabilize the center
of gravity.9 Taken together, these data allow us to
speculate that the higher time-to-peak torque for the
Figure 1 - Knee flexor and extensor isokinetic strength measurements for the right (panels A and C) and left (panels B and D) limbs. PT,
peak torque; PT/BW, peak torque normalized to body weight; Flex/Ext, balance between flexors and extensors; TW, total work; Wmax,
maximum work performed during a single repetition. *, p#0.05 for between-group comparisons. #, p=0.06 for between-group
comparisons.
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knee flexors may be implicated in the function and
balance deficits that were previously observed in
children with ALL.3,10 Moreover, the total and maximal
work that was produced during a single repetition were
reduced in the upper and lower limbs, which partially
explains why children with ALL are more prone to
fatigue and weakness.3,10
It is important to note that the strength impairment
was more evident for the extensor muscles than for
the flexor muscles of the lower limb. Although these
findings are difficult to reconcile, one may intuitively
speculate that daily-living activities primarily involve
the activation of the lower-limb extensor muscle groups.
However, this idea cannot be extrapolated to the upper
limbs, thus warranting further investigation into the
causes of the impaired upper-limb extensor strength in
ALL patients.
In conclusion, we report that children who are receiving
maintenance treatment for ALL generally present with
weaker isokinetic strength than their healthy counterparts.
This finding further supports the prescription of exercise
training programs that include strengthening exercises for
patients with ALL, particularly during the maintenance
phase of their therapy.
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